MFA-1 | 139755-30-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: MFA-1
• 英文别名: 17β(4-hydroxyphenylcarbonyl)-androsta-3,5-diene-3-carboxylic acid；17β-(4-hydroxybenzoyl)-3,5-androstadiene-3-yl carboxylic acid；17β-(4-hydroxybenzoyl)-3,5-androstadien-3-yl carboxylic acid；(8alpha,10alpha,13alpha,17beta)-17-[(4-Hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid；(8S,9S,10R,13S,14S,17S)-17-(4-hydroxybenzoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
• CAS: 139755-30-9
• 化学式: C₂₇H₃₂O₄
• 分子量: 420.549
• InChiKey: RPNNXCYIESWDSC-JRZBRKEGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  aqueous potassium hydroxide 、 Methyl 17β-(4-hydroxybenzoyl)-3,5-androstadiene-3-yl carboxylate 生成 MFA-1
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• New intermediates in the synthesis of 17beta-acyl-3-carboxy-androsta-3,5-dienes
  申请人：MERCK & CO. INC.

  公开号：EP0465123A2

  公开（公告）日：1992-01-08

  New intermediates in the synthesis of 17β-acyl-3-carboxy-androsta-3,5-dienes, of the formula : wherein R2 is 2-thiopyridyl and R3 is C1-C4 alkoxycarbonyl, C1-C4alkoxy, or trifluoromethylsulfonyloxy. The above compounds are useful intermediates in producing testosterone 5α-reductase inhibitors which are useful topically for treatment of acne, seborrhea, female hirsutism, and systemically in treatment of benign prostatic hypertrophy.

  合成 17β-acyl-3-carboxy-androsta-3,5 dienes 的新中间体，其式为 ： 式中 R2 是 2-巯基吡啶和 R3 是 C1-C4 烷氧基羰基、C1-C4 烷氧基或 三氟甲基磺酰氧基。上述化合物是生产睾酮 5α 还原酶抑制剂的有用中间体，可用于局部治疗痤疮、脂溢性皮炎和女性多毛症，也可用于全身治疗良性前列腺肥大。
• N-monosubstituted adamantyl/norbornanyl 17beta-carbamides of3-carboxy-androst-3,5-dienes
  申请人：MERCK & CO. INC.

  公开号：EP0465141A2

  公开（公告）日：1992-01-08

  N-Monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors of the formula : wherein R is a hydrocarbon radical selected from substituted or unsubstituted 1- or 2-adamantyl or 1-, 2-or 7-norbornanyl and pharmaceutically acceptable salts or esters thereof. Also described is a pharmaceutical formulation. The above compounds are active as testosterone 5a-reductase inhibitors and thus are useful topically for treatment of acne, seborrhea, female hirsutiam, and systemically in treatment of benign prostatic hypertrophy.

  3-羧基-3,5-雄甾二烯的 N-单取代金刚烷基/降冰片烷基 17β- 氨基甲酸酯作为睾酮 5α 还原酶抑制剂的式： 其中 R 是选自取代或未取代的 1-或 2-金刚烷基或 1-、2-或 7-降冰片烷基的烃基及其药学上可接受的盐或酯。还描述了一种药物制剂。上述化合物作为睾酮 5a 还原酶抑制剂具有活性，因此可用于局部治疗痤疮、脂溢性皮炎、女性多毛症，也可用于全身治疗良性前列腺肥大。
• 17Beta-acyl-3-androsta-3,5-dienes as testosterone 5alpha-reductase inhibitors
  申请人：MERCK & CO. INC.

  公开号：EP0528485A1

  公开（公告）日：1993-02-24

  17β-Acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors of the formula: wherein R isC₁-C₆ linear or branched alkyl; C₃-C₈ cycloalkyl, which can be substituted with C₁-C₄ alkoxy or C₁-C₄ linear/branched alkyl; C₆-C₁₂ aryl, which can be substituted with one or more of: -OH, -OC₁-C₄ alkyl, C₁-C₄ alkyl, -(CH₂)mOH, -(CH₂)n COOH, including protected -OH, where m is 1-4, n is 1-3, and pharmaceutically acceptable salts or esters thereof. Also described is a pharmaceutical formulation. The above compounds are active as testosterone 5a-reductase inhibitors and thus are useful topically for treatment of acne, seborrhea, female hirsutism, and systemically in treatment of benign prostatic hypertrophy.

  17β-酰基-3-羧基雄甾-3,5-二烯作为睾酮 5α 还原酶抑制剂的配方： 其中 R 是 C₁-C₆ 直链或支链烷基；C₃-C₈ 环烷基，可被 C₁-C₄ 烷氧基取代 或 C₁-C₄ 直链/支链烷基；C₆-C₁₂ 芳基，可被以下一种或多种物质取代：-OH、-OC₁-C₄ 烷基、C₁-C₄ 烷基、-(CH₂)mOH、-(CH₂)n COOH，包括受保护的 -OH，其中 m 为 1-4，n 为 1-3，及其药学上可接受的盐或酯。还描述了一种药物制剂。上述化合物作为睾酮 5a 还原酶抑制剂具有活性，因此可用于局部治疗痤疮、脂溢性皮炎和女性多毛症，也可用于全身治疗良性前列腺肥大。
• Bile acid receptor agonism for treating addiction
  申请人：Vanderbilt University

  公开号：US10064876B2

  公开（公告）日：2018-09-04

  Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.

  本发明公开了用于治疗受试者成瘾的组合物和方法。特别是，公开了治疗多巴胺能精神兴奋剂成瘾的组合物和方法。在一些实施方案中，通过激动受试者体内的胆汁酸受体来治疗成瘾。例如，在一些实施方案中，该方法包括向受试者施用治疗有效量的组合物，该组合物包含治疗有效量的胆汁酸受体激动剂。在一些实施方案中，该方法包括以适合增加受试者体内循环胆汁酸的方式，通过手术转移受试者体内的胆汁酸。
• PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN
  申请人：MERCK & CO. INC.

  公开号：EP0576603A1

  公开（公告）日：1994-01-05